Crinetics Pharmaceuticals (CRNX) News Today $55.37 +0.74 (+1.35%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns "Market Outperform" Rating from JMP SecuritiesDecember 18 at 1:55 AM | americanbankingnews.comCrinetics Pharmaceuticals Strengthens Leadership with New AppointmentDecember 17 at 5:55 AM | markets.businessinsider.comFranklin Resources Inc. Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Franklin Resources Inc. increased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 61.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,390,110 shares of the company's stoDecember 17 at 5:01 AM | marketbeat.comBarclays PLC Purchases 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Barclays PLC raised its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 75.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 207,712 shares of the company'December 17 at 4:02 AM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest UpdateCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 6,010,000 shares, a decline of 7.5% from the November 15th total of 6,500,000 shares. Based on an average daily trading volume, of 713,200 shares, the short-interest ratio is presently 8.4 days.December 16 at 5:42 PM | marketbeat.comCrinetics Pharmaceuticals' (CRNX) Market Outperform Rating Reiterated at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $87.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday.December 16 at 9:51 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Addus Homecare (ADUS)December 16 at 5:24 AM | markets.businessinsider.comLord Abbett & CO. LLC Has $38.13 Million Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lord Abbett & CO. LLC lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 746,118 shares of the company's stock after selling 141,8December 15 at 6:00 AM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by State Street CorpState Street Corp grew its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 0.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,838,484 shares ofDecember 14, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $70.18 Average PT from AnalystsDecember 12, 2024 | americanbankingnews.comBNP Paribas Financial Markets Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)BNP Paribas Financial Markets increased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 134.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,942 shaDecember 11, 2024 | marketbeat.comCrinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 | globenewswire.comCrinetics announces FDA acceptance of NDA for paltusotineDecember 10, 2024 | markets.businessinsider.comPromising Prospects for Crinetics Pharmaceuticals: Buy Rating Driven by Potential Paltusotine Approval and Expansive PipelineDecember 9, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals: FDA To Review NDA For Paltusotine - Quick FactsDecember 9, 2024 | markets.businessinsider.comCrinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with AcromegalyDecember 9, 2024 | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Trimmed by Wellington Management Group LLPWellington Management Group LLP lowered its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,459,691 shares of the company's stock after selling 160,722December 9, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and ten have issuDecember 9, 2024 | marketbeat.comCastleark Management LLC Takes $3.75 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Castleark Management LLC bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 73,340 shares of the company's stock, valued at approximately $3,748,000. CastlearDecember 8, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor oDecember 8, 2024 | marketbeat.comCrinetics price target raised to $87 from $80 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comJanus Henderson Group PLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Janus Henderson Group PLC lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,429,450December 5, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 45.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 77December 4, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 655,418 shares of the company's stock after purchasing an addDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Invests $2.53 Million in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Cinctive Capital Management LP bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 49,445 shares of the company's stock, valued at approximatelyDecember 3, 2024 | marketbeat.comFmr LLC Purchases 358,975 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fmr LLC raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 8.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,455,770 shares of the company's stock after acquiring an additional 358,975 shares duringDecember 3, 2024 | marketbeat.comMartingale Asset Management L P Makes New $1.13 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Martingale Asset Management L P bought a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,074 sharDecember 2, 2024 | marketbeat.comVestal Point Capital LP Takes $10.48 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Vestal Point Capital LP bought a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 205,000 shares of the company's sNovember 29, 2024 | marketbeat.comFisher Asset Management LLC Purchases 37,429 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fisher Asset Management LLC grew its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 8.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 482,099 shaNovember 28, 2024 | marketbeat.com22,348 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Intech Investment Management LLCIntech Investment Management LLC bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 22,348 shares of the company's stock, valuNovember 28, 2024 | marketbeat.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Sells 501 Shares of StockNovember 27, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Natixis Advisors LLCNatixis Advisors LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 36.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,346 sharesNovember 25, 2024 | marketbeat.comPromising Outlook for Crinetics Pharmaceuticals’ Paltusotine in Phase 3 Trial Drives Buy RatingNovember 23, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stake Reduced by BNP PARIBAS ASSET MANAGEMENT Holding S.A.BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 491,381 shares of the company's stock after selling 54,853 shares durNovember 23, 2024 | marketbeat.comPrincipal Financial Group Inc. Acquires 64,504 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Principal Financial Group Inc. raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 488.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,709 shares of the company's stockNovember 22, 2024 | marketbeat.comJennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Jennison Associates LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 0.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,793,614 shares of the company's stock after purchasing an aNovember 20, 2024 | marketbeat.comVictory Capital Management Inc. Purchases 116,657 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Victory Capital Management Inc. increased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 51.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 343,344 shares of the company's stocNovember 20, 2024 | marketbeat.comFirst Turn Management LLC Sells 15,926 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)First Turn Management LLC lessened its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 353,376 shares of the company's stock after selNovember 19, 2024 | marketbeat.comFY2024 EPS Estimates for CRNX Increased by Cantor FitzgeraldCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Crinetics Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company willNovember 18, 2024 | marketbeat.comLeerink Partnrs Has Strong Forecast for CRNX FY2024 EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Leerink Partnrs boosted their FY2024 EPS estimates for shares of Crinetics Pharmaceuticals in a report issued on Wednesday, November 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per sharNovember 18, 2024 | marketbeat.comCrinetics Pharmaceuticals to Participate in Three Upcoming December Investor ConferencesNovember 15, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for CRNX EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst D. Tsao now expects that the company willNovember 15, 2024 | marketbeat.comFY2024 Earnings Forecast for CRNX Issued By Lifesci CapitalCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Stock analysts at Lifesci Capital lowered their FY2024 earnings per share estimates for shares of Crinetics Pharmaceuticals in a report issued on Tuesday, November 12th. Lifesci Capital analyst C. Jubinville now expects that the companNovember 15, 2024 | marketbeat.comUPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual MeetingNovember 14, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 | tmcnet.comCrinetics Pharmaceuticals: Promising Future with Innovative Drug Developments and Strong Financial PositionNovember 14, 2024 | markets.businessinsider.comPositive Outlook for Crinetics Pharmaceuticals: Strategic Advancements and Strong Financial Position Drive Target Price IncreaseNovember 14, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and ten have assNovember 14, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPSCrinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same period last year, the firm posted ($1.01) EPS.November 13, 2024 | marketbeat.comCrinetics Pharmaceuticals: Advancing Cancer Treatment with Novel NDC Platform – A Buy RecommendationNovember 13, 2024 | markets.businessinsider.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼1.120.69▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼136▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Today BeiGene News Today Moderna News Today Viatris News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today Catalent News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
